

In the Claims

Please amend the claims as follows:

1. (Original) A conjugate suited for treating prokaryotic infections, comprising the following components:
 - (a) a transport mediator penetrating the prokaryotic cell membrane; and
 - (b) a peptide nucleic acid (PNA) to be introduced into the prokaryote and directed thereagainst, which inhibits the transcription of a prokaryotic gene.
- 2 (Original) The conjugate according to claim 1, wherein the prokaryote is a bacterium.
3. (Original) The conjugate according to claim 2, wherein the bacterium is a bacterium pathogenic for humans.
4. (Currently amended) The conjugate according to claim 1 ~~any of claims 1 to 3~~, wherein the transport mediator is an antibacterial peptide or protein which can penetrate the prokaryotic cell membrane
5. (Currently amended) The conjugate according to claim 1 ~~any of claims 1 to 4~~, wherein the transport mediator comprises a phage-holin protein comprising one of the amino acid sequences ~~shown in figure 3~~ of SEQ ID NOs: 4 to 31 or a fragment or variant thereof, which can penetrate the prokaryotic cell membrane.
- 6 (Currently amended) The conjugate according to claim 1 ~~any of claims 1 to 4~~, wherein the transport mediator comprises a defensin.
7. The conjugate according to claim 1 ~~any of claims 1 to 6~~, wherein the peptide nucleic acid (PNA) is directed against a gene giving antibiotic resistance.

8. (Original) The conjugate according to claim 7, wherein the antibiotic resistance is a resistance to penicillin, ampicillin, kanamycin or tetracycline.
9. (Currently amended) The conjugate according to claim 1 ~~any of claims 1-8~~, which has the following structure:
transport mediator-spacer-peptide nucleic acid (PNA).
10. (Original) The conjugate or conjugate mixture according to claim 9, wherein the spacer is polylysine, polyglycine or poly(glycine/lysine).
11. (Currently amended) The conjugate according to claim 9 ~~or 10~~, wherein the spacer is linked to the transport mediator via a cleavable disulfide bridge.
12. (Currently amended) The conjugate according to claim 7 ~~any of claims 7 to 11~~, wherein the peptide nucleic acid comprises the sequence H₂N-ATTGTTAGATTTCAT-COOH (SEQ ID NO:1).
13. (Currently amended) A medicament ~~containing~~ comprising a conjugate according to any of claims 1-12 the conjugate according to claim 1.
14. (Original) The medicament according to claim 13, further comprising at least one antibiotic for which the prokaryote was re-sensitized by administering the conjugate.
15. (Currently amended) A method for treating a prokaryotic infection comprising the step of administering the conjugate according to claim 1 ~~Use of a conjugate according to any of claims 1 to 12 or the composition defined in claim 14 for treating a prokaryotic infection.~~
16. (Currently amended) ~~Use~~ The method according to claim 15, wherein the prokaryotic infection is caused by a prokaryote which is resistant to at least one antibiotic.
17. (New) The method according to claim 16, wherein further at least one antibiotic for which the prokaryote was re-sensitized by administering the conjugate is administered.

18. (New) The conjugate according to claim 1, wherein the peptide nucleic acid is linked to the transport mediator by a covalent chemical bond.
19. (New) The conjugate according to claim 10, wherein the spacer is linked to the transport mediator via a cleavable disulfide bridge.